View Author
Fey, M.F.
(Martin Fey)
patient g-csf leukemia myeloid leukemia survival treatment group hospital chemotherapy psc -833 myeloid study factor -833 cycle granulocyte colony-stimulating factor induction university cr rate center blood percent effect death cancer expression cytarabine cytogenetic trial copyright 2003 massachusetts analysis treatment arm colony-stimulating resistance 2 treatment arms netherland table remission square meter hematology department outcome disease-free survival result granulocyte event-free survival phase multidrug induction chemotherapy disease-free granulocyte-macrophage colony-stimulating factor www.nejm.org randomized ratio event kingdom blast hematopoietic growth factors cytosine arabinoside switzerland psc -833 arm diagnosis event-free relapse abnormality gm-csf value cd 34 cells control function p-glycoprotein hematopoietic antibody germany multidrug resistance number growth square g-csf group meter
2 Most Recent Publications
|
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
(Article)
Holt, B. van der Verhoef, G.E.G. Knauf, W.U. Dugan, M. Shepherd, J. Piccaluga, P.P. Ossenkoppele, G.J. Vellenga, E. Ferrant, A. Fey, M.F. Crump, M. Theobald, M. Sonneveld, P. Selleslag, D. Löwenberg, B. Burnett, A.K. |
2005-01-01
|
|
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
(Article)
Löwenberg, B. Kovacsovics, T. Daenen, S.M.G.J. Ferrant, A. Gratwohl, A. Greef, G.E. de Putten, W.L.J. van Theobald, M. Gmur, J. Boogaerts, M. Verdonck, L.F. Sonneveld, P. Fey, M.F. Huijgens, P. |
2003-01-01
|
